Product
Asciminib
Aliases
ABL001, ABL001 (asciminib), Asciminib single agent
19 clinical trials
20 indications
Indication
Chronic Myelogenous LeukemiaIndication
LeukemiaIndication
MyelogenousIndication
ChronicIndication
BCR-ABL positiveIndication
Chronic Myeloid LeukemiaIndication
Acute Lymphoblastic LeukemiaIndication
Myeloid LeukemiaIndication
Philadelphia chromosomeIndication
Chronic MyeloidIndication
Hematologic DisordersIndication
Philadelphia Chromosome-PositiveIndication
Chronic PhaseIndication
myeloidIndication
Leukemia, MyeloidIndication
Philadelphia Chromosome NegativeIndication
BCR/ABL-positiveIndication
Chronic Myeloid Leukemia in RemissionIndication
Chronic Myeloid Leukemia (CML)Clinical trial
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued TreatmentStatus: Recruiting, Estimated PCD: 2027-08-27
Clinical trial
A Phase II, Single-arm Study of De-escalation and Treatment-free Remission in Patients With Chronic Myeloid Leukemia Treated With Nilotinib in First-line Therapy Followed by a Second Attempt After Nilotinib and Asciminib Combination: DANTE StudyStatus: Active (not recruiting), Estimated PCD: 2026-07-31
Clinical trial
A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase.Status: Recruiting, Estimated PCD: 2027-02-15
Clinical trial
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)Status: Completed, Estimated PCD: 2021-06-03
Clinical trial
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular ResponseStatus: Active (not recruiting), Estimated PCD: 2021-11-08
Clinical trial
A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinase InhibitorsStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.Status: Recruiting, Estimated PCD: 2033-07-01
Clinical trial
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaStatus: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
Asciminib as Initial Therapy With Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia Who do Not Achieve a Deep Molecular Remission (ALERT CML)Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia in Combination With Asciminib and Tyrosine Kinase InhibitorsStatus: Not yet recruiting, Estimated PCD: 2028-08-31
Clinical trial
Phase II Study of Dual Targeting of BCR-ABL1 by Adding the Allosteric Inhibitor ABL001 in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease (MRD) While on Therapy With Tyrosine Kinase InhibitorsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationStatus: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label, Trial Evaluating the Efficacy and Safety of Asciminib Used in Consolidation With Imatinib v. Imatinib to Achieve Treatment-free Remission in Chronic Phase-Chronic Myelogenous Leukemia PatientsStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic PhaseStatus: Active (not recruiting), Estimated PCD: 2023-11-28
Clinical trial
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase InhibitorsStatus: Active (not recruiting), Estimated PCD: 2020-05-25
Clinical trial
Frontline Asciminib Combination in Chronic Phase CMLStatus: Active (not recruiting), Estimated PCD: 2027-12-01
Clinical trial
A Prospective, Multicenter, Single-arm, Open-label, Phase IV, Post-authorization Interventional Study to Assess the Safety and Efficacy of Asciminib in Indian Patients With Ph+ CML-CP (Without T315I Mutation), Previously Treated With Two or More Tyrosine Kinase Inhibitors and Ph+ CML-CP With T315I MutationStatus: Not yet recruiting, Estimated PCD: 2025-04-23
Clinical trial
Asciminib as Single Agent or in Combination With Nilotinib in the 1st-line Treatment of BCR-ABL1+ Chronic Myeloid Leukemia: a Randomized GIMEMA-GELMC Phase II Study PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLStatus: Not yet recruiting, Estimated PCD: 2028-09-01